Investor Presentaiton

Oncology Opdivo Opdualag TIGIT Bispecific DGK Inhibitor AR LDD ΙΟ Extending IO leadership while diversifying beyond 10 Extending leadership in 10 Subcutaneous nivolumab: Potential to benefit patients into early 2030s with data anticipated this year Opdualag: 3rd approved IO agent; Approved in 1L melanoma; Phase 3 studies in adjuvant melanoma and mCRC ongoing - Ongoing Phase 2 studies in HCC and lung to inform Phase 3 program Select next-gen 10 . BMS-986442: Differentiated TIGIT bispecific antibody targeting both TIGIT and CD96 DGK inhibitor: Potential transformational, oral dual inhibitor in solid tumors Diversifying beyond IO • AR LDD: Significant opportunity in mCRPC with data expected early next year; initiating pivotal trial in next 18 months repotrectinib: Potential best-in-class, next generation ROS1/NTRK inhibitor; PDUFA November 27, 2023 Addressing oncologic diseases impacting 1.2M+1 patients Ill Bristol Myers Squibb™ 1. 2023 estimates from Decision Resource Group & BMS Internal Analysis across indications in the U.S. & EU5 Not for Product Promotional Use 109

View entire presentation